Madrigal Pharmaceuticals, Inc. MDGL EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s EPS (diluted)?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported EPS (diluted) of -$3.25 in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s EPS (diluted) changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s EPS (diluted) decreased by 24.5% year-over-year, from -$2.61 to -$3.25.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s EPS (diluted)?
- Over 3 years (2021 to 2025), Madrigal Pharmaceuticals, Inc.'s EPS (diluted) has grown at a -11.4% compound annual growth rate (CAGR), from -$14.61 to -$10.15.
- What does EPS (diluted) mean?
- The profit per share calculated as if all potential shares that could be created were already issued.
- How do you interpret EPS (diluted)?
- A decrease relative to basic EPS highlights the potential dilution impact of employee stock plans or convertible instruments.
- How does EPS (diluted) compare across companies?
- Standardized reporting requirement that allows investors to compare the potential dilution impact across different companies.